Staying on TRK: Addressing Clinical Challenges and Improving Outcomes in NTRK Fusion–Positive Cancers

Hear from the experts on how the latest clinical data inform the treatment of patients with NTRK fusions. Review their insights in an on-demand webcast adapted from a live webinar along with downloadable slidesets.

Share

Program Content

Activities

NTRK Fusion Testing
Rationale for Targeting TRK Fusions in Solid Tumors and Implementing NTRK Gene Testing in the Clinic
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2021

Expires: June 10, 2022

1<sup>st</sup> Gen TRK Inhibitors
The Activity and Safety of First-Generation TRK Inhibitors in NTRK Fusion–Positive Cancers
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2021

Expires: June 10, 2022

2nd Gen TRK Inhibitors
Overcoming Acquired Resistance With Second-Generation TRK Inhibitors
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2021

Expires: June 10, 2022

<i>EP</i>: NTRK Fusion-Positive Cancer
ExpressPoints
Staying on TRK: Addressing Clinical Challenges and Improving Outcomes in NTRK Fusion–Positive Cancers
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2021

Expires: June 15, 2022

No activities added yet

Faculty

cover img faculity

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

cover img faculity

Alexander E. Drilon, MD

Chief, Early Drug Development Service
Memorial Sloan Kettering Cancer Center
New York, New York

cover img faculity

Theodore Laetsch, MD

Associate Professor
Division of Oncology
Department of Pediatrics
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group